2025 Free Cash Flow Guidance: $1.6 billion to $1.9 billion. Teva Pharmaceutical Industries Ltd (NYSE:TEVA) reported a 9% increase in revenue for 2024, reaching $16.5 billion, driven by strong ...

Teva Pharmaceutical Industries' Q4 2024 results were strong, but 2025 guidance underwhelmed, causing a sharp stock sell-off. Management's cautious 2025 guidance sets a low bar, likely to be ...

RESIDENTS in Runcorn have woken up to the exciting news that they have won the People’s Postcode Lottery. Those that are signed up to the Postcode Lottery and live in WA7 3AW have won £1,000 this ...

A NEW shop offering ‘amazing’ deals is opening in Runcorn Old Town. Less Than Retail will be based ‘in the heart of Runcorn’ on Church Street. The business, which’ specialises in liquidation stock, ...

Shares of Teva Pharmaceutical Industries (NYSE: TEVA) were slipping Wednesday. The company's stock lost 13.5% as of 1:15 p.m. ET. The leg down comes as the S&P 500 (SNPINDEX: ^GSPC) and Nasdaq ...

at Wrexham and Runcorn, and an offence of dangerous driving - which also took place at Runcorn. Joshua Gorst, prosecuting, told the court that on September 29 last year, police on duty attempted ...

The FDA has accepted Alvotech (NASDAQ:ALVO) and Teva's (NYSE:TEVA) Biologics License Applications for AVT05, their proposed biosimilar to the anti-inflammatory drugs Simponi and Simponi Aria.

After years of legal wrangling surrounding Teva’s Copaxone, the latest hit to the lucrative multiple sclerosis drug comes in the form of a safety-related boxed warning. The label update ...

Daniel Halliwell claimed he had only been travelling at about 70 to 80mph (112 to 128km/h) when he hit the Ford Fiesta on the A558 Daresbury Expressway in Runcorn, Cheshire, at about 17:05 BST on ...

On January 10, 2025, Teva Pharmaceutical Industries Ltd. and Samsung Bioepis Co., Ltd. announced that they entered into a licensing agreement to commercialize EPYSQLI® (eculizumab-aagh), Samsung ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...